Great post thanks Harry. In reference to Rob that's great he is...

First 22581 Last

Share
Profile

Follow
DTLP

942 Posts.

223

18/04/24

06:57

Post #: 73397768
Share

Originally posted by Harry58: ↑

The last two weeks has certainly presented an emotional roller-coaster for many Imugene shareholders.
The majority in my view are optimistic that the science will deliver positive outcomes for cancer sufferers and ultimately financial reward.

The problem for many is their perception of timing ... this is a speculative stock that requires patient capital. And of course as the saying goes, speculation leads to expectation which (if not met) can result in frustration.

An understanding of time frames in clinical trials will assist in setting expectations.
The company however, does not assist in this regard when they state in the MAST trial announcements that "the trial commenced in May 2022 and is anticipated to run for approximately 24 months".
Any punter would correctly interpret this to mean that the trial will finish in May 2024.
But no, according to the clinical trial information the estimated trial completion date has always been recorded as 31st January 2025.

In the last fortnight shareholders have been treated to no less than 5 price sensitive announcements.

3/4/2024 - Imugene to present at 2024 Cholangialcarcinoma Conference
4/4/2024 - Oncolytic Virotherapy CF33 Patent granted in China.
8/4/2024 - Vaxinia and HER-vaxx featured at AACR annual meeting.
15/4/2024 - Bile Tract Cancer Study opens after MAST High Dose Trial clearance.
16/4/2024 - Imugene and Kincel Bio Announce Strategic Partnership

This exceeded my expectations but as is the case for many of our price sensitive announcements the SP suffered adding more pain, anguish and frustration for shareholders.

Clearly a reset of expectations is required ....
the Vaxinia MAST trial has just cleared the 5th dosing cohort in IT Monotherapy at 3x10^8 without any safety issues and is commencing an expansion study cohort of 10 patients in an unmet need of Bile Tract Cancer. And of course there is the forthcoming read-out of the Azer-cel confirmation trial due this quarter, not to mention the OnCARlytic combination trial that has commenced on the 11th March 2024.

The development and progress of clinical trials under the leadership of Leslie and her team has been amazing and deserves full recognition.

And finally I want to acknowledge the patients in our trials who are fighting this horrible disease that hopefully our virotherapies can deliver improved outcomes.

In another post I noted that in the announcement for Expansion into Bile Tract Cancer, the cancer indications for the cleared 5th Monotherapy IT cohort were reported as "thymic carcinoma, triple negative breast cancer and cholangiocarcinoma".

And in light of comments made by Rob from Brisbane aka Rock_Robster on the Colon Cancer Support Group who commenced his dosing regimen on the 19th March for liver cancer at St Vincents in Melbourne it would appear that he is in the 6th dosing cohort of 1x10^9.
Rob has recently completed his third scheduled treatment on day 21 of his first cycle and is doing well.

GLTAH - Go Team Imugene
.

Expand

Great post thanks Harry. In reference to Rob that's great he is doing well. His update the other day didn't sound so great and it has since been removed. Do you have comm's with him outside of the Colon Chat forum where that update was posted? I seriously hope he has pulled through that rough patch he described and is on his way to recovery. After his third dose at the higher dosage it will be pretty amazing to follow his progress. Fingers crossed for him and all patients on the trial.

IMU Price at posting: 8.3¢ Sentiment: Hold Disclosure: Held
14 Upvote

0 Great analysis

Reply

There are more pages in this discussion • 1,010 more messages in this thread...

First 22581 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 6.9¢		Change 0.000(0.00%)		Mkt cap ! $505.0M

Open	High	Low	Value	Volume
7.0¢	7.1¢	6.8¢	$1.427M	20.55M

Buyers (Bids)

No.	Vol.	Price($)
1	57517	6.9¢

Sellers (Offers)

Price($)	Vol.	No.
7.0¢	667419	9

View Market Depth

No.	Vol.	Price($)
1	57517	0.069
32	2289313	0.068
17	2338899	0.067
13	1712188	0.066
36	1652866	0.065

Price($)	Vol.	No.
0.070	667419	9
0.071	4459857	9
0.072	2269414	14
0.073	1105338	9
0.074	802935	8

Last trade - 16.10pm 21/05/2024 (20 minute delay)


Last 6.9¢		Change 0.000 ( 0.29 %)
Open	High	Low	Volume
6.9¢	7.1¢	6.8¢	7149293
Last updated 15.59pm 21/05/2024 ?

IMU (ASX) Chart

Great post thanks Harry. In reference to Rob that's great he is...

Featured News

The High Fiving ASX oil and gas stock star champions are...

Gas critical to Australia's renewable future, say political and industry leaders.

Market Close: ASX closes flattish as traders shrug off new NASDAQ record

Pacific Edge revenues up, cash costs down on reorganisation

Havilah drills molybdenum up to 0.21% and gold at 4.79 g/t at SA's Kalkaroo

Buyers (Bids)

Sellers (Offers)

Featured News

Great post thanks Harry. In reference to Rob that's great he is...

Featured News

Top Stories

The High Fiving ASX oil and gas stock star champions are...

Gas critical to Australia's renewable future, say political and industry leaders.

Market Close: ASX closes flattish as traders shrug off new NASDAQ record

Pacific Edge revenues up, cash costs down on reorganisation

Havilah drills molybdenum up to 0.21% and gold at 4.79 g/t at SA's Kalkaroo

Buyers (Bids)

Sellers (Offers)

Featured News